MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Drug Utilization Review
20 questions · exam conditions
0:00
Drug Utilization ReviewQuestion 1 of 20

A pharmacist's DUR system generates an alert for every prescription in a high-volume pharmacy. The pharmacist develops a routine of clicking through alerts without reviewing them to maintain workflow speed. Which of the following best analyzes this practice?

This practice is acceptable because DUR alert systems are designed to generate alerts that pharmacists are expected to override most of the time.
This practice violates DUR obligations by bypassing required clinical review, risking patient safety through failure to assess potential drug therapy issues.
This practice satisfies DUR requirements as long as the pharmacist reviews at least the highest-severity alerts.
This practice is acceptable in high-volume settings because workflow demands create an implicit exception to strict DUR requirements.
← Back to quizzes

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Drug Utilization Review

Practice Drug Utilization Review in MPJE: Multistate Pharmacy Jurisprudence Examination with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Drug Utilization Review, giving you a quick way to practice the rules, question types, and explanations that matter most for MPJE: Multistate Pharmacy Jurisprudence Examination.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A pharmacist's DUR system generates an alert for every prescription in a high-volume pharmacy. The pharmacist develops a routine of clicking through alerts without reviewing them to maintain workflow speed. Which of the following best analyzes this practice?

  1. This practice is acceptable because DUR alert systems are designed to generate alerts that pharmacists are expected to override most of the time.
  2. This practice violates DUR obligations by bypassing required clinical review, risking patient safety through failure to assess potential drug therapy issues. (correct answer)
  3. This practice satisfies DUR requirements as long as the pharmacist reviews at least the highest-severity alerts.
  4. This practice is acceptable in high-volume settings because workflow demands create an implicit exception to strict DUR requirements.
Explanation: DUR requires genuine clinical review -- not mechanical processing. A pattern of reflexively clicking through all alerts without clinical evaluation defeats the purpose of DUR and creates patient safety risk. B correctly identifies this as a DUR compliance violation. A is incorrect because DUR alerts are meant to be clinically evaluated, not presumptively overridden; the system generates alerts to prompt review, not to be systematically bypassed. C is incorrect because selective alert review limited to the highest-severity alerts still fails to assess lower-severity alerts that may be clinically significant; all alerts require at least a brief clinical assessment before override. D is incorrect because workflow volume demands do not create exceptions to DUR obligations; high volume requires efficient review processes, not abandonment of review.

Question 2

A pharmacist reviewing a prescription for an elderly patient identifies that the prescribed medication is on the Beers Criteria list of potentially inappropriate medications for older adults. Which of the following best describes the pharmacist's DUR obligation?

  1. Review the patient's profile, discuss concerns with prescriber, suggest alternatives, document actions, and provide enhanced counseling if dispensing. (correct answer)
  2. Refuse to dispense any medication on the Beers Criteria list because they are categorically inappropriate for older adults.
  3. Dispense the medication without comment because Beers Criteria are guidelines, not binding legal requirements.
  4. Dispense the medication but inform the patient to see a geriatrician before continuing the medication.
Explanation: Beers Criteria flags require clinical DUR judgment applied to the individual patient. The pharmacist should contact the prescriber to discuss the concern and potential alternatives, document the intervention, and if the prescriber confirms after discussion, dispense with counseling on monitoring. A correctly describes this individualized approach. B is incorrect because Beers listings identify potential concerns, not categorical prohibitions. C is incorrect because dismissing Beers Criteria flags without any clinical review fails the DUR obligation. D is incorrect because referring to a geriatrician without first addressing the concern with the prescriber bypasses the required DUR intervention.

Question 3

A pharmacist performs DUR on a new prescription for an antidepressant for a patient who is already taking a different antidepressant. The pharmacist believes this may be therapeutic duplication. Which of the following most accurately describes when two antidepressants would NOT constitute therapeutic duplication?

  1. Two antidepressants always constitute therapeutic duplication and must never be dispensed together.
  2. Two antidepressants from different classes may be combined for treatment-resistant depression. (correct answer)
  3. Two antidepressants from the same class are always appropriate together.
  4. Therapeutic duplication rules do not apply to psychiatric medications.
Explanation: Intentional combination of two antidepressants -- particularly from different classes -- is a recognized clinical practice for augmentation or treatment-resistant depression. When prescribed intentionally with documented clinical rationale, it is not therapeutic duplication in the clinical DUR sense. B correctly identifies this distinction. A is incorrect because combination antidepressant therapy is a legitimate clinical practice. C is incorrect because same-class combinations raise greater duplication concerns and are less commonly clinically intentional. D is incorrect because DUR principles including therapeutic duplication apply to psychiatric medications.

Question 4

A pharmacist performs DUR before dispensing a refill of metformin and notices a new laboratory result in the patient's profile showing the patient's eGFR has dropped to a level at which metformin use is contraindicated. The prescriber has not yet been notified. Which of the following best applies?

  1. Dispense the refill because the patient has been on metformin for years and the prescriber will review labs at the next appointment.
  2. Withhold the refill and immediately contact the prescriber to report the new lab finding and the contraindication; document the intervention and await prescriber guidance before dispensing. (correct answer)
  3. Dispense the refill with enhanced counseling about kidney monitoring.
  4. Reduce the quantity to a 7-day supply while contacting the prescriber.
Explanation: A new laboratory finding indicating a contraindication to the patient's current medication requires immediate prescriber notification and withholding the refill pending clinical review. B correctly identifies this urgent intervention. A is incorrect because deferring to the next appointment when a known contraindication exists is a patient safety failure. C is incorrect because enhanced counseling does not address the underlying safety concern when a contraindication has emerged. D is incorrect because dispensing any quantity of a contraindicated drug without prescriber guidance creates liability and patient risk.

Question 5

A high-volume retail pharmacy implements a policy requiring pharmacists to complete DUR on all new prescriptions within 60 seconds to maintain patient flow. Which of the following best analyzes this policy?

  1. The policy is appropriate because DUR should be efficient to support high-volume operations.
  2. The policy is appropriate because 60 seconds is sufficient for any DUR review.
  3. The policy may compromise DUR quality, as time limits can hinder thorough clinical reviews. (correct answer)
  4. The policy is appropriate because state DUR laws specify maximum review times for high-volume settings.
Explanation: Imposing rigid time limits on DUR creates the risk of inadequate clinical review, particularly for complex patients. DUR requirements mandate genuinely meaningful clinical assessment, which cannot always be completed in a fixed time. C correctly identifies the compliance concern. A is incorrect because efficiency goals cannot override clinical thoroughness requirements. B is incorrect because 60 seconds is clearly insufficient for complex multi-drug patients requiring thorough DUR. D is incorrect because state DUR laws do not specify maximum review times for high-volume settings.

Question 6

A pharmacy chain routes all DUR alerts to a centralized pharmacist in another state before the branch can dispense. The centralized pharmacist reviews the alert and either approves or modifies the dispense. Which of the following best analyzes this centralized DUR model?

  1. This model is non-compliant because all DUR must be performed by the dispensing pharmacist at the point of dispensing.
  2. Compliance depends on state law; some states allow centralized DUR, others require it at the dispensing location. (correct answer)
  3. This model is fully compliant in all states because DEA registration covers all pharmacy activities.
  4. This model is non-compliant because DUR may only be performed by the pharmacist-in-charge.
Explanation: Centralized DUR performed by a remote pharmacist is recognized in many states under shared-services or central fill provisions, but compliance depends on the specific requirements of the state where dispensing occurs. The remote pharmacist must hold appropriate licensure and have access to complete patient profile data. B correctly identifies this state-specific compliance analysis. A is incorrect because many states permit remote DUR by licensed pharmacists under shared-services frameworks. C is incorrect because DEA registration governs controlled substance authority, not DUR compliance. D is incorrect because DUR may be performed by pharmacists other than the PIC under appropriate shared-services arrangements.

Question 7

A pharmacist performs prospective DUR and identifies a potential drug-drug interaction between a newly prescribed medication and a medication the patient already takes. Which of the following best describes the required action?

  1. Dispense the prescription and note the interaction in the patient's profile for future reference.
  2. Refuse to dispense the prescription permanently because a drug interaction has been identified.
  3. Contact the prescriber to discuss the interaction and determine if dispensing is appropriate. (correct answer)
  4. Dispense the prescription but counsel the patient extensively to monitor for interaction effects.
Explanation: When a significant drug-drug interaction is identified during DUR, the pharmacist must contact the prescriber before dispensing to discuss the interaction and determine the appropriate clinical course of action. The intervention must be documented. C correctly describes this workflow. A is incorrect because noting without acting fails the DUR obligation when a significant interaction exists. B is incorrect because not all identified interactions require permanent refusal; clinical severity determines the response. D is incorrect because dispensing without prescriber consultation when a significant interaction exists shifts responsibility to the patient and bypasses the required clinical intervention.

Question 8

A patient presents a prescription for a new medication. A DUR alert flags a potential interaction with a supplement the patient listed on her profile. The interaction is rated as minor significance. Which of the following best describes how the pharmacist should handle this alert?

  1. Use clinical judgment to assess significance; document decision, counsel patient, and proceed if insignificant. Contact prescriber if uncertain. (correct answer)
  2. Always contact the prescriber for every DUR alert regardless of severity rating.
  3. Override all minor-rated alerts without documentation because minor interactions never require action.
  4. Refuse to dispense any prescription when an interaction alert is present until the patient removes the supplement from her profile.
Explanation: DUR alerts require clinical judgment -- pharmacists must evaluate whether an alert represents a clinically meaningful concern for this specific patient. Minor-rated interactions may often be managed with counseling rather than prescriber contact, but the pharmacist's clinical assessment drives the response. Documentation of the decision is required. A correctly describes this individualized clinical approach. B is incorrect because requiring prescriber contact for every alert regardless of severity is unnecessary and impractical. C is incorrect because overriding all minor alerts without documentation fails the DUR obligation. D is incorrect because refusing to dispense based solely on a minor alert is disproportionate.

Question 9

A pharmacist performs DUR and identifies a significant drug-disease contraindication -- the patient has documented kidney disease and has been prescribed a medication that is contraindicated in renal failure. Which of the following best describes the appropriate action?

  1. Dispense the medication because the prescriber is aware of the patient's kidney disease and made this prescribing decision.
  2. Refuse to dispense and inform the patient that the prescription cannot be filled.
  3. Contact the prescriber to discuss the contraindication and withhold dispensing until receiving further instructions. Document the intervention. (correct answer)
  4. Dispense a half quantity and counsel the patient to take a reduced dose to mitigate the renal risk.
Explanation: A drug-disease contraindication identified during DUR requires immediate prescriber contact and withholding the prescription pending clinical review. The pharmacist must document the intervention and, if the prescriber confirms, document the rationale. C correctly describes this process. A is incorrect because assuming the prescriber is aware does not discharge the pharmacist's DUR obligation. B is incorrect because permanent refusal without prescriber consultation is premature; the prescriber may have a clinical justification. D is incorrect because adjusting quantity or dose without prescriber authorization is outside the pharmacist's scope.

Question 10

A state law requires pharmacies to conduct and document retrospective DUR quarterly, reviewing dispensing data for patterns of drug misuse, overutilization, fraud, or inappropriate prescribing. A pharmacy has not conducted its quarterly retrospective DUR in six months. Which of the following best analyzes the compliance concern?

  1. The pharmacy is non-compliant due to missing two required quarterly retrospective DUR reviews, violating state-mandated frequency requirements. (correct answer)
  2. There is no compliance concern because retrospective DUR is purely voluntary.
  3. There is no compliance concern because the pharmacy has been conducting prospective DUR, which satisfies both prospective and retrospective obligations.
  4. There is no compliance concern because no patient harm has been identified from the missed reviews.
Explanation: When state law mandates retrospective DUR at a specified frequency, failure to conduct it at that frequency is a regulatory violation. Six months without a quarterly review means two missed cycles. A correctly identifies the compliance concern. B is incorrect because state-mandated retrospective DUR is not voluntary. C is incorrect because prospective and retrospective DUR serve different purposes and one does not satisfy the other. D is incorrect because identified patient harm is not a prerequisite for a procedural compliance violation.

Question 11

A DUR system flags a drug interaction between a proton pump inhibitor and clopidogrel. The interaction is clinically controversial -- some guidelines suggest clinical significance while others find no meaningful effect. How should the pharmacist proceed?

  1. Override the alert because the clinical significance is controversial.
  2. Refuse to dispense because any flagged interaction requires prescription cancellation.
  3. Dispense without counseling because the interaction is unproven.
  4. Consult the prescriber, document assessment, and counsel the patient on risks. (correct answer)
Explanation: Clinically controversial interactions require pharmacist judgment informed by current evidence and clinical context. Consulting the prescriber -- particularly for high-risk patients -- and documenting the assessment are appropriate. D correctly describes this evidence-based, patient-centered approach. A is incorrect because overriding without any clinical evaluation fails the DUR obligation. B is incorrect because controversial evidence does not mandate prescription cancellation. C is incorrect because counseling remains important even for uncertain interactions, especially for high-risk patients.

Question 12

Which of the following best describes the pharmacist's DUR obligation when a newly presented prescription triggers an alert for a potentially life-threatening drug interaction and the prescriber is immediately reachable by phone?

  1. Dispense the prescription and rely on patient counseling to mitigate the interaction risk.
  2. Override the DUR alert and proceed because DUR alerts are designed to be overridden.
  3. Refuse to dispense permanently and direct the patient to an emergency room.
  4. Contact the prescriber, inform them of the interaction, and await their instructions before dispensing. (correct answer)
Explanation: A potentially life-threatening drug interaction requires immediate prescriber contact and withholding the prescription pending clinical guidance. Documentation of the entire interaction -- the alert, the prescriber conversation, the prescriber's instructions, and the outcome -- is required. D correctly describes this complete intervention. A is incorrect because counseling alone does not address a potentially life-threatening interaction. B is incorrect because overriding a life-threatening interaction alert without clinical review is a DUR failure. C is incorrect because permanent refusal without prescriber consultation is premature; the prescriber may confirm clinical urgency justifying the prescription.

Question 13

A state board requires pharmacies to maintain records of all prospective DUR interventions. A pharmacy's audit reveals it has been documenting DUR overrides but not DUR interventions where the prescription was modified or not dispensed. Which of the following best analyzes the compliance concern?

  1. There is no compliance concern because documenting overrides is the most important DUR record.
  2. There is no compliance concern because modifications and non-dispenses are self-evident from the dispensing record.
  3. The pharmacy is non-compliant; DUR records must include all interventions, not just overrides. (correct answer)
  4. The compliance concern is minor because DUR interventions are the least common type of DUR outcome.
Explanation: Complete DUR recordkeeping must capture all intervention types, not only overrides. Documenting only overrides omits the interventions most likely to reflect genuine drug therapy problem identification. C correctly identifies the compliance deficiency. A is incorrect because overrides, while important, are not the only required DUR record. B is incorrect because the dispensing record does not capture the clinical rationale for modifications or non-dispenses. D is incorrect because interventions resulting in modification or non-dispense are actually the most clinically significant DUR outcomes and must be documented.

Question 14

A pharmacy's DUR program identifies that a patient has been filling the same medication at multiple pharmacies -- a pattern consistent with potential drug seeking. Which of the following best describes how DUR intersects with this situation?

  1. DUR does not address medication-seeking behavior; it applies only to clinical drug therapy problems.
  2. DUR applies only to interactions and contraindications; multiple pharmacy fills are a DEA matter only.
  3. DUR requires the pharmacist to immediately report the patient to law enforcement.
  4. DUR alerts the pharmacist to review overutilization patterns and consult the PDMP before dispensing. (correct answer)
Explanation: DUR encompasses overutilization as well as clinical drug therapy problems. A pattern of multiple pharmacy fills may trigger an overutilization DUR alert, requiring the pharmacist to investigate, consult the PDMP, and apply corresponding responsibility analysis before dispensing. D correctly identifies this DUR dimension. A is incorrect because overutilization is explicitly a DUR category alongside clinical drug therapy problems. B is incorrect because PDMP consultation and corresponding responsibility are directly relevant to this DUR scenario, not exclusively DEA matters. C is incorrect because DUR findings trigger clinical and professional investigation obligations; immediate mandatory law enforcement reporting is not the required DUR response to a potential overutilization pattern.

Question 15

During DUR for a new opioid prescription, the pharmacist notes the patient has a documented allergy to the opioid class listed in her profile. The patient insists she no longer has the allergy and it was a misidentification years ago. Which of the following best applies?

  1. Dispense the opioid because the patient has the right to override her own allergy profile.
  2. Refuse to dispense because documented allergies are absolute contraindications that cannot be removed.
  3. Consult the prescriber to verify allergy status before dispensing or updating the patient's profile. (correct answer)
  4. Dispense the opioid after the pharmacist's clinical assessment concludes the allergy entry is likely an error.
Explanation: A documented drug allergy is a DUR concern that requires prescriber involvement before dispensing. Patients cannot unilaterally remove their own allergy flags from pharmacy records, and the pharmacist should not override an allergy alert based solely on the patient's verbal statement. C correctly identifies the required process: contact the prescriber, communicate the patient's claim, and withhold dispensing until the prescriber formally reviews and addresses the allergy documentation. A is incorrect because patients cannot override clinical allergy documentation without prescriber involvement; the allergy flag is a clinical record, not a patient preference setting. B is incorrect because allergy entries can be corrected with proper clinical authorization if they were genuinely erroneous; a blanket prohibition on ever dispensing is too absolute. D is incorrect because the pharmacist's independent clinical assessment is insufficient to override a documented allergy; prescriber authorization is required before the profile can be updated and the prescription dispensed.

Question 16

A DUR program identifies a patient who is prescribed both an ACE inhibitor and an ARB simultaneously -- a combination associated with increased risk of hypotension and renal impairment. The prescriber confirms the combination is intentional for a specific nephroprotective purpose and documents the rationale. Which of the following best describes the pharmacist's remaining obligations?

  1. No further action is needed after the prescriber confirms intent.
  2. The pharmacist should still refuse to dispense because the combination is categorically dangerous.
  3. The pharmacist should dispense only one of the two medications.
  4. Dispense and counsel on risks, document prescriber verification and patient counseling. (correct answer)
Explanation: After prescriber confirmation of intentional combination therapy, the pharmacist's obligation shifts to dispensing with targeted counseling and documentation. The patient must be informed of the specific risks of dual blockade including hypotension and electrolyte monitoring requirements. D correctly identifies these remaining obligations. A is incorrect because prescriber confirmation does not eliminate the pharmacist's counseling and documentation obligations. B is incorrect because intentional combination therapy with documented clinical rationale and prescriber confirmation does not warrant refusal. C is incorrect because dispensing only one without prescriber direction to modify is not appropriate after the prescriber confirmed the full regimen.

Question 17

A pharmacist's prospective DUR identifies that a patient's new prescription for amoxicillin is a therapeutic duplication -- the patient already has an active prescription for another penicillin antibiotic for the same infection. Which of the following best describes the appropriate response?

  1. Dispense the amoxicillin because the prescriber ordered it and the pharmacist should not question clinical decisions.
  2. Contact the prescriber to verify the prescription and document the clarification before dispensing. (correct answer)
  3. Dispense the amoxicillin and inform the patient to stop the prior antibiotic.
  4. Substitute the amoxicillin with a non-penicillin antibiotic to resolve the therapeutic duplication.
Explanation: Therapeutic duplication identified during DUR requires prescriber contact to clarify intent before dispensing. Dispensing two antibiotics from the same class for the same infection without verification could harm the patient or reflect a prescribing error. B correctly identifies this intervention. A is incorrect because the pharmacist has a DUR obligation to address identified problems, not simply defer to the order. C is incorrect because instructing the patient to stop a prior prescription without prescriber authorization is outside the pharmacist's scope. D is incorrect because substituting to a different antibiotic without prescriber authorization is not appropriate.

Question 18

A patient presents a prescription for a blood thinner. During prospective DUR, the pharmacist notes the patient is also taking aspirin. The prescriber's office confirms both were intentionally prescribed and the clinical rationale is documented. Which of the following best describes the pharmacist's next obligation?

  1. Dispense the medication and counsel the patient on potential bleeding risks associated with combination therapy. (correct answer)
  2. Refuse to dispense because bleeding risk from combination therapy is too high to justify dispensing.
  3. Dispense without counseling because the prescriber has already addressed the combination.
  4. Dispense only a partial fill until the patient sees the prescriber for a follow-up.
Explanation: Once a DUR concern has been resolved through prescriber verification and documentation, the pharmacist should dispense and counsel the patient on the clinical implications of the combination therapy -- specifically the enhanced bleeding risk and warning signs. A correctly identifies this complete response. B is incorrect because intentional combination therapy with documented clinical rationale does not warrant refusal. C is incorrect because prescriber verification of the combination does not eliminate the pharmacist's independent counseling obligation. D is incorrect because partial fill without a specific clinical indication is not the appropriate response.

Question 19

Under OBRA '90, which of the following best describes prospective drug utilization review (DUR) as it applies to pharmacists dispensing Medicaid prescriptions?

  1. Prospective DUR is an optional quality improvement activity that pharmacists may perform at their discretion.
  2. Prospective DUR involves reviewing prescriptions and patient history to identify potential drug therapy issues. (correct answer)
  3. Prospective DUR applies only to Schedule II controlled substances dispensed to Medicaid patients.
  4. Prospective DUR requires the pharmacist to contact the prescriber before dispensing every new prescription.
Explanation: OBRA '90 established prospective DUR as a mandatory clinical review that pharmacists must perform before dispensing prescriptions to Medicaid patients -- reviewing the prescription against the patient's medication history to identify drug therapy problems including drug interactions, therapeutic duplications, inappropriate drug or dose, contraindications, and adverse drug reactions. B correctly describes this obligation. A is incorrect because prospective DUR is mandatory, not optional. C is incorrect because it applies to all prescriptions, not only Schedule II controlled substances. D is incorrect because prescriber contact is required only when problems are identified, not before every dispense.

Question 20

A pharmacist identifies during DUR that a pediatric patient has been prescribed an adult dose of an antibiotic. Which of the following best applies?

  1. Dispense as prescribed because the prescriber calculated the dose based on clinical factors not visible to the pharmacist.
  2. Dispense a reduced dose using the pharmacist's own weight-based calculation without contacting the prescriber.
  3. Contact the prescriber to verify the dose is safe for the child's age and weight before dispensing. (correct answer)
  4. Dispense half the prescribed quantity as a precaution and refill when the parent calls to confirm the dose.
Explanation: An apparent overdose for a pediatric patient identified during DUR requires prescriber verification before dispensing. The pharmacist should withhold dispensing and contact the prescriber. C correctly describes this required action. A is incorrect because the DUR obligation exists precisely to catch prescribing errors; deferring without verification is not appropriate. B is incorrect because unilaterally adjusting the dose without prescriber authorization is outside the pharmacist's scope. D is incorrect because dispensing half without prescriber guidance is both clinically inappropriate and outside the pharmacist's authority.